The DCGI approved Bharat Biotech’s first intranasal Covid vaccine on Tuesday for use as the primary immunisation against the infection in adults above 18.
Lauding the achievement, Health Minister Dr Mansukh Mandaviya said, it is a ‘Big Boost to India’s Fight Against COVID-19’
Mandaviya tweeted, Big Boost to India’s Fight Against COVID-19! Bharat Biotech’s ChAd36-SARS-CoV-S COVID-19 (Chimpanzee Adenovirus Vectored) recombinant nasal vaccine approved by @CDSCO_INDIA_INF for primary immunization against COVID-19 in the 18+ age group for restricted use in an emergency situation.
Big Boost to India's Fight Against COVID-19!
Bharat Biotech's ChAd36-SARS-CoV-S COVID-19 (Chimpanzee Adenovirus Vectored) recombinant nasal vaccine approved by @CDSCO_INDIA_INF for primary immunization against COVID-19 in 18+ age group for restricted use in emergency situation.
— Dr Mansukh Mandaviya (@mansukhmandviya) September 6, 2022
Bharat Biotech stated last month that it had conducted two separate trials for its intranasal Covid vaccine, one as a primary dose schedule and another as a booster dose, for subjects who have been double vaccinated with the two commonly administered Covid vaccines in India. These trials were phase-III and booster dose trials for the intranasal Covid-19 vaccine.
According to a statement from BBIL, it has been shown in controlled trials to be secure, well-tolerate any-to-administer in participants.
According to the firm, national regulatory authorities have received the data from both of the Phase III human clinical trials that have been filed for approval.
“If approved, this intranasal vaccine will make it easier to deploy in mass immunisation campaigns with an easy to administer formulation and delivery device. Vectored vaccines also enable faster development of targeted vaccines in response to emerging variants of concern,” Bharat Biotech joint managing director Suchhitra K Ella said.